$7.01
Today
as of Jul 22, 16:46 ET
Last 30 days
Recent Press Releases & News
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
Aura Biosciences Completes Enrollment in Phase 3 Trial of Belzupacap Sarotalocan for Early Choroidal Melanoma
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma
Overview
52-week range
$4.73
$9.54
47% of range
Avg surprise (last 3)
-12.6%
Avg reaction (last 2)
+1.6%
50% positive
Latest IV / EM
26%
EM ±2.2% · $8 · Jul 17
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Mon May 11, 2026 | Mar/2026 | $-0.50 | $-0.40 | -25.0% | +9.1% | -2.5% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.40 | — | — | — | — | financials |
| Wed Aug 13, 2025 | Jun/2025 | $-0.47 | $-0.49 | +4.1% | — | — | earnings |
| Thu May 15, 2025 | Mar/2025 | $-0.55 | $-0.47 | -17.0% | — | +5.7% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.42 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.41 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.40 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.48 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.48 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 12, 2026 | Jun/2026 | OTHER | -$0.41 | -$0.47 | +12.8% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-35M | — | $-28M | $-29M | $-29M | — | $-23M | $-23M |
| Net income | $-34M | — | $-26M | $-27M | $-27M | — | $-21M | $-20M |
| EPS (diluted) | $-0.50 | — | $-0.40 | $-0.47 | $-0.55 | — | $-0.42 | $-0.41 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $85M | $60M | $48M | $107M | $38M | $32M | $25M | $30M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $119M | $150M | $170M | $184M | $135M | $161M | $183M | $196M |
| Total assets | $138M | $169M | $190M | $204M | $155M | $183M | $205M | $218M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $30M | $33M | $33M | $30M | $27M | $31M | $31M | $27M |
| Total equity | $107M | $137M | $157M | $175M | $128M | $152M | $175M | $191M |